Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Lilly pads oral GLP-1 case with pair of phase 3 diabetes wins
Lilly's oral GLP-1 drug candidate racked up wins against placebo and AZ's Farxiga to stay on track to seek approval in Type 2 diabetes next year.
Nick Paul Taylor
Oct 15, 2025 9:48am
FDA clears Biolinq's color-coded sensor patch for glucose ranges
Sep 29, 2025 11:30am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
Medtronic debuts Abbott Instinct CGM as MiniMed 780G enters T2D
Sep 2, 2025 11:00am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
